Stockscreener 앱 받기
122.74
0.36%
-0.44
시간 외 거래:
123.29
0.55
+0.45%
Gilead Sciences Inc 주식(GILD)의 최신 뉴스
Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026 - Finviz
What's Driving the Market Sentiment Around Gilead Sciences Inc? - Benzinga
Los Angeles Capital Management LLC Purchases 1,223,895 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Ascent Group LLC Buys 11,926 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Why Gilead Sciences (GILD) Dipped More Than Broader Market Today - sharewise.com
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead (GILD) reaches pricing agreement with US government to lower drug costs - MSN
Gilead (GILD) Reaches Pricing Agreement with US Government to Lower Drug Costs - Insider Monkey
Daniel Patrick O'day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Abacus FCF Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences (GILD) An Affordable Healthcare Stocks to Invest In? - Insider Monkey
Gilead stock nudges up after Bernstein flags limited Medicaid pricing hit - ts2.tech
After 25 Years, Recurrent Genital Herpes Treatment Gains Corporate Partner - Vax-Before-Travel
November phase III successes led by HIV wins from Gilead, Merck - BioWorld MedTech
Bernstein reiterates Gilead Sciences stock rating, citing minimal Medicaid impact - Investing.com
Repare Therapeutics Signs Asset Purchase Agreement With Gilead Sciences - TradingView — Track All Markets
Liver Fibrosis Treatment Market Is Booming So Rapidly | Gilead Sciences, Inc., Merck & Co., Inc. - openPR.com
Sapient Capital LLC Sells 8,077 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Bought by E. Ohman J or Asset Management AB - MarketBeat
Gilead Sciences exercises option to license Assembly Biosciences Helicase-Primase Inhibitor programs for... - Medical Dialogues
Meyer Handelman Co. Has $38.56 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Highland Capital Management LLC Invests $1.76 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc.'s (NASDAQ:GILD) Prospects Need A Boost To Lift Shares - 富途牛牛
Pacer Advisors Inc. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology
Norden Group LLC Has $3.40 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (NASDAQ:GILD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
RPTX Stock Soars Pre-Market After Gilead Agrees To Acquire Investigational Cancer Drug - Stocktwits
December 2028 Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise - marketscreener.com
Vontobel Holding Ltd. Acquires 394,567 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug - Investing.com Canada
Swedbank AB Acquires 58,405 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Repare Therapeutics Stock Rises As Gilead Secures Cancer Asset For $30 Million - Benzinga
Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Investing News Network
Gilead Sciences (GILD) to Acquire Repare Therapeutics' Key Asset - GuruFocus
Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million By Investing.com - Investing.com Canada
Gilead to buy Repare Thera’s cancer candidate for up to $30M - MSN
Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment - marketscreener.com
Gilead to acquire Repare Therapeutics’ PolΘ inhibitor for $30 million - Investing.com
Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration - marketscreener.com
Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration - Bluefield Daily Telegraph
Global X Japan Co. Ltd. Acquires 11,034 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Stock (GILD) After Hours: What to Know Before the Market Opens on Dec. 24, 2025 - ts2.tech
OFI Invest Asset Management Has $42.01 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Reduced by U.S. Capital Wealth Advisors LLC - MarketBeat
Confluence Investment Management LLC Sells 16,861 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Exchange Traded Concepts LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Sahm
Gilead (GILD) Stock: Edges Slightly Lower After HSV Licensing Update - CoinCentral
Gilead Sciences (GILD) Stock After Hours on Dec. 22, 2025: What’s Moving Shares and What to Watch Before Tuesday’s Open - ts2.tech
Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs - Stocktwits
Gilead Sciences to Present at Upcoming Investor Conference - Business Wire
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025) - ts2.tech
Gilead Sciences (GILD) Licenses Assembly Bio's Herpes Drug Progr - GuruFocus
UK approves Gilead’s twice-yearly HIV PrEP drug - Yahoo
Gilead pays $35M to license pair of HSV assets from Assembly Bio pact - Fierce Biotech
Gilead Sciences Picks 14-Year Company Veteran as GC - Law.com
Gilead exercises option for Assembly Bio’s herpes treatment programs - Investing.com
0.36%
자본화:
|
볼륨(24시간):